Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-20152 in Healthy Participants
NCT07503015Phase 1Not yet recruiting
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Apr 2026
- Primary completion
- Jan 2027
- Modality
- Biologic
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial comparing HS-20152 with Placebo (2 arms). Primary endpoint: Incidence and severity of adverse events and/or serious adverse events up to 24 weeks. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
HS-20152
Beyond the preview
Go deeper on NCT07503015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07503015.